MX2009009703A - Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo. - Google Patents

Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.

Info

Publication number: MX2009009703A
Authority: MX; Mexico
Prior art keywords: methyl; solid preparation; fluorobenzonitrile; pyrimidinyl; amino
Prior art date: 2007-03-13

Application number

MX2009009703A

Other languages

English (en)

Spanish (es)

Inventor

Yusuke Murakawa

Miyuki Hohokabe

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-13

Filing date

2008-03-12

Publication date

2010-03-03

2008-03-12 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2010-03-03 Publication of MX2009009703A publication Critical patent/MX2009009703A/es

Links

238000002360 preparation method Methods 0.000 title abstract 3
239000007787 solid Substances 0.000 title abstract 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
229920000168 Microcrystalline cellulose Polymers 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
235000019813 microcrystalline cellulose Nutrition 0.000 abstract 3
239000008108 microcrystalline cellulose Substances 0.000 abstract 3
229940016286 microcrystalline cellulose Drugs 0.000 abstract 3
150000003839 salts Chemical class 0.000 abstract 3
239000008187 granular material Substances 0.000 abstract 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
230000000996 additive effect Effects 0.000 abstract 1
235000019359 magnesium stearate Nutrition 0.000 abstract 1
IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MX2009009703A 2007-03-13 2008-03-12 Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo. MX2009009703A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007064245		2007-03-13
PCT/JP2008/055016 WO2008114800A2 (fr)	2007-03-13	2008-03-12	Préparation solide

Publications (1)

Publication Number	Publication Date
MX2009009703A true MX2009009703A (es)	2010-03-03

Family

ID=39409986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2009009703A MX2009009703A (es)	2007-03-13	2008-03-12	Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.

Country Status (10)

Country	Link
US (1)	US7994183B2 (fr)
EP (1)	EP2120885A2 (fr)
JP (1)	JP5432720B2 (fr)
AR (1)	AR065698A1 (fr)
CA (1)	CA2680684A1 (fr)
CL (1)	CL2008000727A1 (fr)
MX (1)	MX2009009703A (fr)
PE (1)	PE20090015A1 (fr)
TW (1)	TW200900094A (fr)
WO (1)	WO2008114800A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en)	2008-08-15	2014-08-29	Boehringer Ingelheim Int	Purin derivatives for use in the treatment of fab-related diseases
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es)	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
AU2010212823B2 (en)	2009-02-13	2016-01-28	Boehringer Ingelheim International Gmbh	Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EA201270204A1 (ru) *	2009-07-28	2012-08-30	Такеда Фармасьютикал Компани Лимитед	Таблетка
NZ598170A (en)	2009-10-02	2014-06-27	Boehringer Ingelheim Int	Pharmaceutical compositions comprising bi-1356 and metformin
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102791701B (zh)	2009-12-30	2014-02-12	深圳信立泰药业股份有限公司	作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
EP2547339A1 (fr)	2010-03-18	2013-01-23	Boehringer Ingelheim International GmbH	Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
WO2011161161A1 (fr)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Thérapie du diabète
JO3753B1 (ar)	2011-10-14	2021-01-31	Otsuka Pharma Co Ltd	قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
DK2851075T3 (da) *	2012-05-14	2022-01-31	Shionogi & Co	Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2013179307A2 (fr) *	2012-05-29	2013-12-05	Mylan Laboratories Limited	Compositions pharmaceutiques stabilisées de saxagliptine
AR092843A1 (es)	2012-06-05	2015-05-06	Takeda Pharmaceuticals Co	Preparacion solida
EP2769712A1 (fr) *	2013-02-21	2014-08-27	Siegfried International AG	Formulation pharmaceutique comportant des agglomérats d'inhibiteur DPP-IV et des particules d'inhibiteur DPP-IV
PE20170201A1 (es) *	2014-07-07	2017-04-08	Novartis Ag	Formas de dosificacion farmaceutica
CN104825413B (zh) *	2015-05-25	2019-12-20	浙江华海药业股份有限公司	一种含有琥珀酸曲格列汀的口服片剂及其制备方法
US10548848B2 (en) *	2015-06-17	2020-02-04	Hexal Ag	Alogliptin formulation
CN105596341B (zh) *	2016-03-14	2018-08-10	石家庄四药有限公司	一种琥珀酸曲格列汀固体制剂及制备方法
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
WO2022208096A1 (fr)	2021-04-01	2022-10-06	Sun Chemical Corporation	Compositions aqueuses pour jet d'encre comprenant des dispersions de polyuréthane à fonction hydroxy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5009897A (en) *	1988-06-24	1991-04-23	Abbott Laboratories	Pharmaceutical granules and tablets made therefrom
JP2514078B2 (ja) *	1988-08-22	1996-07-10	エスエス製薬株式会社	圧縮成型製剤
NZ230763A (en) *	1988-09-27	1991-10-25	Takeda Chemical Industries Ltd	Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
JP3004758B2 (ja) *	1991-04-17	2000-01-31	旭化成工業株式会社	結合性、崩壊性に優れる加工澱粉
JP4633469B2 (ja) *	2002-12-16	2011-02-16	キッセイ薬品工業株式会社	経口固形医薬
RU2766487C2 (ru)	2004-01-20	2022-03-15	Новартис Аг	Композиция и способ прямого прессования
CA2554809C (fr) *	2004-02-05	2014-04-29	Probiodrug Ag	Nouveaux inhibiteurs de la glutaminyl-cyclase comportant de la n thiouree alkyle et de l'imidazolyl substitue par thioamide
UA85871C2 (uk) *	2004-03-15	2009-03-10	Такеда Фармасьютікал Компані Лімітед	Інгібітори дипептидилпептидази
MY147393A (en) *	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
MX2009002772A (es) *	2006-09-13	2009-05-28	Takeda Pharmaceutical	Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo.
TW200838536A (en) *	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR065096A1 (es) *	2007-02-01	2009-05-13	Takeda Pharmaceutical	Preparacion solida
US8093236B2 (en) *	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
PE20090987A1 (es) *	2007-08-16	2009-08-14	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido

2008
- 2008-03-12 JP JP2009539324A patent/JP5432720B2/ja active Active
- 2008-03-12 MX MX2009009703A patent/MX2009009703A/es active IP Right Grant
- 2008-03-12 CA CA002680684A patent/CA2680684A1/fr not_active Abandoned
- 2008-03-12 TW TW097108616A patent/TW200900094A/zh unknown
- 2008-03-12 AR ARP080101006A patent/AR065698A1/es unknown
- 2008-03-12 WO PCT/JP2008/055016 patent/WO2008114800A2/fr not_active Ceased
- 2008-03-12 US US12/450,118 patent/US7994183B2/en not_active Expired - Fee Related
- 2008-03-12 EP EP08722406A patent/EP2120885A2/fr not_active Withdrawn
- 2008-03-12 CL CL200800727A patent/CL2008000727A1/es unknown
- 2008-03-12 PE PE2008000467A patent/PE20090015A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CL2008000727A1 (es)	2008-10-17
WO2008114800A3 (fr)	2008-12-24
AR065698A1 (es)	2009-06-24
JP2010521416A (ja)	2010-06-24
WO2008114800A2 (fr)	2008-09-25
US20100105710A1 (en)	2010-04-29
US7994183B2 (en)	2011-08-09
EP2120885A2 (fr)	2009-11-25
CA2680684A1 (fr)	2008-09-25
WO2008114800A8 (fr)	2009-04-09
JP5432720B2 (ja)	2014-03-05
TW200900094A (en)	2009-01-01
PE20090015A1 (es)	2009-01-30

Legal Events

Date	Code	Title	Description
2012-04-20	FG	Grant or registration

Publication	Publication Date	Title
MX2009009703A (es)	2010-03-03	Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.
MX2012001284A (es)	2012-03-26	Tableta.
GEP20125410B (en)	2012-02-27	Solid preparation comprising alogliptin and pioglitazone
MY159522A (en)	2017-01-13	Administration of dipeptidyl peptidase inhibitors
MX2007014892A (es)	2008-04-17	Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
MX2012002480A (es)	2012-03-26	Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
WO2009051119A1 (fr)	2009-04-23	Composé de pyrimidylindoline
IL180597A0 (en)	2007-06-03	Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
WO2006127926A3 (fr)	2007-01-18	Formes cristalline et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one
NZ597595A (en)	2014-08-29	Heterocyclic compounds and uses therof
PL1771178T3 (pl)	2010-01-29	Zastosowanie K-252A i inhibitorów kinazy do zapobiegania lub leczenia patologii związanych z HMGB1
IL195269A0 (en)	2009-08-03	Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
MY146947A (en)	2012-10-15	Antiparasitic agent for fish and method of controlling proliferation of fish parasites
MY148878A (en)	2013-06-14	Stabilized amorphous forms of imatinib mesylate
JO2973B1 (en)	2016-03-15	Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2009060952A1 (fr)	2009-05-14	Nouvelle préparation
EA201071395A1 (ru)	2011-06-30	Ингибитор толерантности к анальгетику
SI1994926T1 (sl)	2010-04-30	Farmacevtske oblike valsartana
UA97348C2 (en)	2012-02-10	HETEROCYCLIC NF-kB INHIBITORS
TW200744583A (en)	2007-12-16	Statin stabilizing dosage formulations
WO2009097973A3 (fr)	2009-10-01	Imidazopyridazines en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments
WO2007138462A3 (fr)	2009-04-23	Formulations orales aqueuses de rispéridone
MX2007013468A (es)	2008-01-21	Composiciones que contienen tanaproget micronizado.
WO2008086128A3 (fr)	2008-09-25	Aminopyrazoles inhibiteurs de kinases
MX2012002209A (es)	2012-07-25	Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.